Please try another search
For the three months ended 31 March 2021, PRA HealthSciences Inc revenues increased 19% to $933.8M. Net incomeincreased 40% to $56.9M. Revenues reflect Clinical Researchsegment increase of 19% to $866.6M, Data Solutions segmentincrease of 17% to $67.1M, United States segment increaseof 19% to $625M, United Kingdom segment increase of 25% to$249.8M. Net income benefited from Interest Expense, netdecrease of 61% to $5.2M (expense).
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Revenue | 933.77 | 873.46 | 796.31 | 729.89 |
Gross Profit | 238.41 | 251.47 | 227.84 | 186.28 |
Operating Income | 69.51 | 96.67 | 124.16 | 43.63 |
Net Income | 56.94 | 51.26 | 91.25 | 13.87 |
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Assets | 4282.74 | 4178.5 | 3839.21 | 3722.8 |
Total Liabilities | 2726.22 | 2699.32 | 2513.95 | 2555.4 |
Total Equity | 1556.52 | 1479.18 | 1325.27 | 1167.4 |
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | 192.21 | 427.18 | 267.1 | 86.47 |
Cash From Investing Activities | -18.73 | -233.9 | -219.23 | -200.83 |
Cash From Financing Activities | 12.05 | 77.43 | 55.52 | 50.61 |
Net Change in Cash | 183.96 | 270.03 | 99.96 | -68.04 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review